Characterizes pharmacokinetics of cefepime in APD patients, suggesting improved dosing strategies for peritonitis treatment.
The International Society for Peritoneal Dialysis (ISPD) guidelines currently recommend intraperitoneal (IP) administration of cefepime, a fourth-generation cephalosporin, as a first-line monotherapy for infectious peritoneal dialysis-associated peritonitis (PDAP). Despite this, data on the pharmacokinetics (PK) of cefepime and its optimal dosing in automated peritoneal dialysis (APD) remain limited. This study aimed to characterize the PK of cefepime in APD patients and to predict the probability of achieving pharmacokinetic/pharmacodynamic (PK/PD) targets during short versus long-dwell periods using Monte Carlo simulations.
No takes yet. Share an insight, caveat, or question.
Tüchler et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: